I don't know if I would feel like taking such test, even it I realize its importance to plan for future therapies...
A new blood test called AR-ctDETECT can predict the prognosis for patients with advanced prostate cancer by analyzing circulating tumor DNA (ctDNA).
The test identified ctDNA in 59% of patients with metastatic prostate cancer, and those with detectable ctDNA had significantly worse overall survival compared to those without.
The AR-ctDETECT test focuses on genes relevant to prostate cancer and hormone resistance, including the androgen receptor. The test may help doctors better understand a patient's cancer and personalize treatment plans.
The study, published in Nature Communications, demonstrated that ctDNA detection is associated with worse survival in a phase 3 cohort.
The researchers plan to further explore using the test to predict patient outcomes with specific treatments.
